TORONTO and WINNIPEG, Jan. 24 /CNW/ - Cangene today announces that the
U.S. Food and Drug Administration ("FDA") has approved Accretropin(TM)
(somatropin (rDNA origin)) Injection, Cangene's recombinant human growth
hormone ("rhGH"). The drug is indicated for treatment of pediatric patients
who have growth failure due to an inadequate secretion of normal endogenous
growth hormone, or treatment of short stature associated with Turner Syndrome
in pediatric patients whose epiphyses are not closed. "This is a significant
accomplishment. Accretropin(TM) is our first recombinant product approval.
Cangene continues to demonstrate that it can take new products from
development to approval effectively," said Dr. John Langstaff, president and
CEO of Cangene. "We now have four FDA-approved drugs."
